Mylan

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

It looks like there is no end is sight to the EpiPen shortage and Mylan (MYL) stock is taking a beating Wednesday on the news.
The post EpiPen Shortage: Mylan (MYL) Stock Falls on Continued Scarce Supply appeared first on InvestorPlace.

EpiPen Shortage: Mylan (MYL) Stock Falls on Continued Scarce Supply

A persistent EpiPen shortage is forcing patients and pharmacists to go to great lengths to get hold of the lifesaving injectors. EpiPens have been hard to get since at least May 2018.

EpiPen Shortage Leaves Patients Scrambling Just To Stay Alive

Gap Inc

Nordstrom

Kraft Heinz

Kohl's

Macy's

The stock market is having its best year since 1997, but these six S&P 500 stocks didn't get an invite to the party.
The post 6 Worst S&P 500 Stocks of 2019 (So Far) appeared first on InvestorPlace.

6 Worst S&P 500 Stocks of 2019 (So Far)

Teva Pharmaceutical

Buying stocks that have declined to bargain levels due to negative headlines and sentiment can pay off big.

Mylan And Teva: History Shows Buying The Current Pain Could Be Your Big Future Gain

Mylan NV (NASDAQ:MYL) might be a good case study for MBA candidates on how not to run a company.

The Only Hope for Mylan Shareholders Appears to Be a Breakup or Sale

Mylan (MYL) reported earnings 30 days ago. What's next for the stock?

Mylan (MYL) Down 18.8% Since Last Earnings Report: Can It Rebound?

Amneal Pharmaceuticals

Lannett Company

The industry drew the ire of 44 state attorneys general alleging widespread conspiracy to inflate drug prices.

Here's Why Generic-Drug Manufacturers Lost As Much As 43.2% in May

Investors need to pay close attention to Mylan (MYL) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Mylan (MYL) Stock

Teva Pharmaceutical and Mylan could be on the hook for billions in damages after a lawsuit accused pharmaceutical companies of colluding to fix generic drug prices, an analyst said Friday.

An Antitrust Lawsuit Could Cost Generic Pharmas Billions Of Dollars

Shares of Mylan N.V. MYL, -2.25% sank 2.7% in morning trade toward a 7 1/2-year low, after Fitch Ratings revised its outlook on the generic drug maker's credit rating to negative from stable, putting the rating in danger of a downgrade to "junk" status.

Mylan's stock falls toward 7 1/2-year low; credit rating now in danger of downgrade to 'junk' at Fitch

Mallinckrodt PLC

Forty-four states have brought a lawsuit against the industry.

Here's Why Generic-Drug Manufacturers Were Down Monday

Mylan stock jumped Thursday on a report the Carlyle Group could be prepping to bid on it following the pharmaceutical company's lackluster first-quarter sales report earlier this week.

Mylan Stock Jumps On Rumored Bid After Lackluster First Quarter

Mylan N.V. (MYL) CEO Heather Bresch on Q1 2019 Results - Earnings Call Transcript

Although the generic pharma company posted an earnings beat, it failed to clarify how it would reverse declining sales.

Mylan Beats Estimates but Gets Slammed on Guidance

The drugmaker's challenges in the U.S. generics market and problems at a manufacturing facility weighed on its first-quarter revenue and earnings.

Mylan's Struggles Continue in the First Quarter

Mylan's (MYL) earnings beat estimates but sales miss the same in the first quarter of 2019.

Mylan's (MYL) Q1 Earnings Beat Estimates, Revenues Miss

The drugmaker's Q1 update is weighing on its share price.

Why Mylan Stock Is Sinking Today

Attorneys general from several states have notified Mylan N.V. MYL, -17.20% that they intend to file a new complaint against the drugmaker alleging anticompetitive conduct with respect to some of its generic drugs.

Mylan notified that several states intend to file new complaint alleging anticompetitive conduct

When Mylan N.V. released its first-quarter financial results before the markets opened on Tuesday, the company posted $0.82 in earnings per share (EPS) and $2.5 billion in revenue.

Why Mylan Is Getting Absolutely Crushed

Mylan (MYL) delivered earnings and revenue surprises of 3.80% and -7.32%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Mylan (MYL) Surpasses Q1 Earnings Estimates

Mylan NV missed first-quarter revenue estimates on Tuesday, hurt by lower demand for its products and manufacturing problems at its Morgantown plant, sending its shares down nearly 8 percent.

Mylan revenue misses on Morgantown plant issues, shares fall 8 percent

Drugmaker Mylan missed Wall Street estimates for quarterly revenue, hurt by restructuring at its Morgantown plant in West Virginia and a stronger dollar,.

Mylan quarterly revenue misses estimates, shares fall

Allergan

Allergan and Mylan earnings beat first-quarter estimates Tuesday, but Mylan stock tumbled after sales came in light.

Allergan, Mylan Top Earnings Views, But Mylan Dives On Sales Lag

Shares of Mylan N.V.  fell 4.5% in premarket trade Tuesday after the drugmaker reported a revenue shortfall that offset a profit beat.

Mylan shares down 4.5% after drugmaker misses on revenue

Mylan N.V. is scheduled to release its first-quarter financial results before the markets open on Tuesday.

News for Mylan Stock (MYL)